Literature DB >> 11986951

Preferential expression of the transcription coactivator HTIF1alpha gene in acute myeloid leukemia and MDS-related AML.

D Gandini1, C De Angeli, G Aguiari, E Manzati, F Lanza, P P Pandolfi, A Cuneo, G L Castoldi, L del Senno.   

Abstract

HTIF1alpha, a transcription coactivator which is able to mediate RARalpha activity and functionally interact with PML, is encoded by a gene on chromosome 7q32-34, which is a critical region in acute myeloid leukemias (AML). With the assumption that this gene may be related to AML, we investigated the HTIF1alpha DNA structure and RNA expression in leukemic cells from 36 M1-M5 AML patients (28 "de novo" and eight "secondary" to myelodysplastic syndrome (MDS)). Abnormal HTIF1alpha DNA fragments were never found, whereas loss of HTIF1alpha DNA was observed in the patients with chromosome 7q32 deletion and translocation, and in one case without detectable chromosome 7 abnormality. HTIF1alpha RNA was found in acute myelocytic leukemic blasts, and was almost undetectable in normal mononuclear cells. The expression varied among the patients: higher in M1 to M3 subtypes, with the highest values in M1; low levels were constantly observed in M4 and M5 AML. In addition, HTIF1alpha was significantly overexpressed in MDS-related AML (MDR-AML), but not in MDS. We also found that HTIF1alpha expression was high in myeloid cell lines. In myeloblastic HL60 and promyelocytic NB4 cells, induced to differentiate along the monocytic-macrophage pathway by TPA or vitamin D3, HTIF1alpha expression decreased, whereas it was maintained at high levels on induction to granulocytic differentiation by RA or DMSO. In K562 cells, HTIF1alpha RNA levels did not change after hemin-induced erythroid differentiation. These results suggest that HTIF1alpha could play a role in myeloid differentiation, being distinctly regulated in hematopoietic lineages.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11986951     DOI: 10.1038/sj.leu.2402452

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

1.  TRIM proteins and cancer.

Authors:  Shigetsugu Hatakeyama
Journal:  Nat Rev Cancer       Date:  2011-10-07       Impact factor: 60.716

2.  Prognostic significance of TRIM24/TIF-1α gene expression in breast cancer.

Authors:  Monique Chambon; Béatrice Orsetti; Marie-Laurence Berthe; Caroline Bascoul-Mollevi; Carmen Rodriguez; Vanessa Duong; Michel Gleizes; Sandrine Thénot; Frédéric Bibeau; Charles Theillet; Vincent Cavaillès
Journal:  Am J Pathol       Date:  2011-04       Impact factor: 4.307

Review 3.  The TRIM proteins in cancer: from expression to emerging regulatory mechanisms.

Authors:  A Mohammadi; M S Pour Abbasi; S Khorrami; S Khodamoradi; Z Mohammadi Goldar; F Ebrahimzadeh
Journal:  Clin Transl Oncol       Date:  2021-10-13       Impact factor: 3.405

4.  Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells.

Authors:  Jacopo Albanesi; Nelida Ines Noguera; Cristina Banella; Tommaso Colangelo; Elisabetta De Marinis; Stefano Leone; Orazio Palumbo; Maria Teresa Voso; Paolo Ascenzi; Clara Nervi; Fabrizio Bianchi; Alessandra di Masi
Journal:  Cells       Date:  2020-11-05       Impact factor: 6.600

5.  TRIM24 overexpression is common in locally advanced head and neck squamous cell carcinoma and correlates with aggressive malignant phenotypes.

Authors:  Zhibin Cui; Wei Cao; Jiang Li; Xiaomeng Song; Li Mao; Wantao Chen
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

6.  TRIM66 overexpresssion contributes to osteosarcoma carcinogenesis and indicates poor survival outcome.

Authors:  Yu Chen; Yongfei Guo; Haisong Yang; Guodong Shi; Guohua Xu; Jiangang Shi; Na Yin; Deyu Chen
Journal:  Oncotarget       Date:  2015-09-15

Review 7.  TRIM proteins in blood cancers.

Authors:  Lisa J Crawford; Cliona K Johnston; Alexandra E Irvine
Journal:  J Cell Commun Signal       Date:  2017-11-06       Impact factor: 5.782

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.